---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014477"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:26:40.340134+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics Q2 net loss $52.3M; advances DYNE-251 and DYNE-101 trials

## Summary
- Net loss of $52.3M ($1.01 per share) vs. $30.0M ($0.58) in Q2 2021; R&D expenses rose to $46.7M from $23.9M.
- Cash, equivalents and marketable securities $291.8M as of June 30, 2022, expected to fund operations into H2 2024.
- FDA lifted clinical hold on DYNE-251 IND for Phase 1/2 MAD trial in DMD patients amenable to exon 51 skipping; dosing expected mid-2022.
- New Zealand cleared clinical trial application for DYNE-101 Phase 1/2 MAD trial in DM1; patient dosing expected mid-2022.
- Presented preclinical data for DYNE-101 at ASGCT showing robust DMPK RNA knockdown in muscle models.

## SEC filing metadata
- accession: 0000950170-22-014477
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017022014477/0000950170-22-014477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017022014477/dyn-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014477
- JSON: https://secwatch.observer/filing/0000950170-22-014477.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014477.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.